Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.44 |
| ▸ | PDE1A | P54750 | 4/20 | 0.44 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.44 |
| ▸ | PDE1C | Q14123 | 4/20 | 0.44 |
| ▸ | KHK | P50053 | 6/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | TNKS | O95271 | 2/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5845859 | 1.00 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5883995 | 0.93 | PDE5A (0.49) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5883562 | 0.91 | PDE5A (0.44) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5728930 | 0.91 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5847439 | 0.91 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5728934 | 0.91 | PDE5A (0.43) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5859606 | 0.90 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5860641 | 0.90 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5859600 | 0.90 | PDE5A (0.42) | PDE5APDE1APDE1BPDE1CKHK | |
| SCHEMBL5860610 | 0.90 | PDE5A (0.41) | PDE5APDE1APDE1BPDE1CKHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2685983-B1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-05-18 | — | — | EP | claimed |
| US-20140038967-A1 | NOVEL USE FOR IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2014-02-06 | — | — | US | claimed |
| EP-2685983-A1 | NOVEL USE OF IMIDAZOTRIAZINONES | Algiax Pharmaceuticals GmbH (DE) | 2014-01-22 | — | — | EP | claimed |
| WO-2012123406-A1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-09-20 | — | — | WO | claimed |
| US-7115602-B2 | Heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | claimed |
| US-20050065153-A1 | Novel heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | claimed |
| US-20170119775-A1 | TREATMENT OF COGNITIVE DISORDERS | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170119775-A1 | TREATMENT OF COGNITIVE DISORDERS | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| US-20170119775-A1 | TREATMENT OF COGNITIVE DISORDERS | ALGIAX PHARMACEUTICALS GMBH (DE) | 2017-05-04 | — | — | US | disclosed |
| EP-3125900-A1 | TREATMENT OF COGNITIVE DISORDERS | Algiax Pharmaceuticals GmbH (DE) | 2017-02-08 | — | — | EP | disclosed |
| EP-2685983-B1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| EP-2685983-B1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-05-18 | — | — | EP | disclosed |
| US-20160022688-A1 | NOVEL USE FOR IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2016-01-28 | — | — | US | disclosed |
| WO-2012125951-A1 | CELLULASE COMPOSITIONS AND METHODS OF USING THE SAME FOR IMPROVED CONVERSION OF LIGNOCELLULOSIC BIOMASS INTO FERMENTABLE SUGARS | DANISCO US INC (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123406-A1 | NOVEL USE OF IMIDAZOTRIAZINONES | ALGIAX PHARMACEUTICALS GMBH (DE) | 2012-09-20 | — | — | WO | disclosed |
| US-7115602-B2 | Heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-20050065153-A1 | Novel heterocycles 3 | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-24 | — | — | US | disclosed |
| EP-1399447-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | Bayer HealthCare AG (DE) | 2004-03-24 | — | — | EP | disclosed |
| US-20030139415-A1 | Novel heterocycles 3 | BAYER HEALTHCARE AKTIENGESELLSCHAFT (DE) | 2003-07-24 | — | — | US | disclosed |
| WO-2002098879-A1 | IMIDAZOTRIAZINONES DERIVATIVES AND THEIR USE AGAINST INFLAMMATORY PROCESSES AND/OR IMMUNE DISEASES | BAYER HEALTHCARE AG (DE) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139415-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885 |
| US-20140038967-A1 | NOVEL USE FOR IMIDAZOTRIAZINONES | ATP6V1B2, INA, CAMK2B | PDE5A 764/4885PDE1A 35/4885PDE1B 39/4885 |
| US-20170119775-A1 | TREATMENT OF COGNITIVE DISORDERS | SLC18A2, SLC18A3, SLC6A3 | PDE5A 856/4885PDE1A 276/4885PDE1B 282/4885 |
| US-20160022688-A1 | NOVEL USE FOR IMIDAZOTRIAZINONES | ATP6V1B2, INA, PMP22 | PDE5A 657/4885PDE1A 39/4885PDE1B 48/4885 |
| US-20050065153-A1 | Novel heterocycles 3 | NFATC1, NOD2, NFKBIA | PDE5A 1993/4885PDE1A 3380/4885PDE1B 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.